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Background: Invasive pulmonary aspergillosis (IPA) is an infection that primarily affects
immunocompromised hosts, including hematological patients and stem-cell transplant
recipients. The diagnosis of IPA remains challenging, making desirable the availability
of new specific biomarkers. High-throughput methods now allow us to interrogate the
immune system for multiple markers of inflammation with enhanced resolution.
Methods: To determine whether a signature of alveolar cytokines could be associated
with the development of IPA and used as a diagnostic biomarker, we performed a nested
case-control study involving 113 patients at-risk.
Results: Among the 32 analytes tested, IL-1β, IL-6, IL-8, IL-17A, IL-23, and TNFα were
significantly increased among patients with IPA, defining two clusters able to accurately
differentiate cases of infection from controls. Genetic variants previously reported to
confer increased risk of IPA compromised the production of specific cytokines and
impaired their discriminatory potential toward infection. Collectively, our data indicated
that IL-8 was the best performing cytokine, with alveolar levels ≥904 pg/mL predicting
IPA with elevated sensitivity (90%), specificity (73%), and negative predictive value (88%).
Conclusions: These findings highlight the existence of a specific profile of alveolar
cytokines, with IL-8 being the dominant discriminator, whichmight be useful in supporting
current diagnostic approaches for IPA.
Keywords: invasive pulmonary aspergillosis, biomarkers, cytokines/chemokines, bronchoalveolar lavage, fungal
diagnostics
INTRODUCTION
Invasive pulmonary aspergillosis (IPA) is a life-threatening infection caused predominantly by the
opportunistic fungusAspergillus fumigatus (Segal, 2009). It is commonly diagnosed among patients
with immunological deficits, namely those with hematologic malignancies during chemotherapy
or undergoing solid organ or allogeneic hematopoietic cell transplantation (Kontoyiannis et al.,
2010; Pagano et al., 2010; Pappas et al., 2010). There are currently no licensed vaccines, and despite
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improved diagnosis and therapy, management of IPA remains
challenging, with mortality rates of infected patients exceeding
30% (Bitar et al., 2014; Maertens et al., 2016). Given the variable
risk of infection and its clinical outcome among patients with
comparable predisposing clinical and microbiological factors,
susceptibility to IPA is thought to rely largely on genetic
predisposition (Cunha et al., 2013; Camargo and Husain, 2014).
Early diagnosis of IPA is critically required to decrease
morbidity and mortality, particularly in vulnerable populations
of immunocompromised patients, since the delayed initiation of
antifungal therapy may contribute to fatal outcomes (Arvanitis
et al., 2015). However, definitive diagnoses are challenging,
typically because traditional diagnostic tools, such as histology
and culture, are often difficult to obtain, with relatively
low sensitivities, particularly in patients under antifungal
prophylaxis. The incorporation of fungal surrogate markers,
such as galactomannan, into clinical algorithms has facilitated
diagnostic-driven strategies in at-risk patients (Morrissey et al.,
2013). Notwithstanding, treatment of IPA remains mostly
empirical based on a high index of suspicion, combined with
non-specific clinical signs and symptoms, and radiological
findings (Kozel and Wickes, 2014). This results in an excessive
prescription of antifungal drugs, ultimately associated with
a remarkable economic burden to the healthcare systems,
highlighting therefore a pressing demand for new and improved
diagnostic methods for IPA (Oliveira-Coelho et al., 2015).
Our current view of the pathogenesis of IPA identifies the
concerted action of the ciliated epithelium and cells of the innate
immune system, including resident alveolar macrophages and
dendritic cells, and recruited inflammatory cells, as the first
line of defense against inhaled fungal spores (Espinosa and
Rivera, 2016). These cells express a large repertoire of immune
receptors that sense pathogen motifs and drive the secretion
of cytokines and chemokines that control innate and adaptive
immune responses (Carvalho et al., 2012b). Because of their
production in response to infection, specific cytokines and
chemokines, such as interleukin (IL)-6, IL-8, and IL-10, have
been reported at higher concentrations in the serum of patients
suffering from IPA compared to controls (Chai et al., 2010a,b;
Reikvam et al., 2012; Ceesay et al., 2016; Shen et al., 2016).
Remarkably, IL-6 was also reported to discriminate cases of IPA
from Pneumocystis pneumonia in pediatric oncology patients
(Shen et al., 2016), thereby raising the appealing possibility
for cytokine detection in differential fungal diagnostics.
Besides their diagnostic value, certain cytokines have been
endowed with prognostic significance. For example, persistently
elevated levels of circulating IL-6 and IL-8 were identified
as important early predictors of adverse outcomes in IPA
(Chai et al., 2010a).
The genetic profile of the patient is regarded as a critical factor
contributing to the risk of IPA (Cunha et al., 2013). Accordingly,
variants in cytokine and chemokine genes impairing their
expression or functional activity have been disclosed as major
determinants of susceptibility to infection (Mezger et al., 2008;
Wojtowicz et al., 2014; Cunha et al., 2017). Likewise, genetic
variants affecting the β-glucan receptor dectin-1, and known
to predispose to IPA, triggered a significant defect in cytokine
production following experimental fungal infection (Cunha et al.,
2010). Although the list of circulating cytokines and chemokines
that correlate with the risk and clinical outcome of IPA continues
to grow, a systematic profiling of alveolar cytokines during
infection and the evaluation of their diagnostic significance has
never been performed.
To determine whether alveolar cytokines were endowed
with diagnostic potential in IPA, we measured 32 analytes in
bronchoalveolar lavage (BAL) samples from a nested case-control
study involving 113 patients at-risk of infection. We found that a
subset of alveolar cytokines could significantly discriminate cases
of infection from controls. In addition, we identified two distinct
clusters of highly correlated cytokines that were differentially
expressed between cases of IPA and controls. The diagnostic
performance of individual or clustered cytokines was found to
depend on the genetic background of the patient. Taken together,
the results presented herein provide crucial insights into the
pulmonary immune profile of patients with IPA and disclose
individual and clustered cytokines that may serve as important
diagnostic adjuvants in combination with classical diagnostic
methods.
MATERIALS AND METHODS
Patients and Sample Collection
BAL and serum samples were collected from hospitalized
adult patients (≥18 years of age) during routine diagnostic
workup following suspicion of infection at the Leuven University
Hospitals, Leuven, Belgium. The demographic and clinical
characteristics of the patients enrolled are summarized in
Table 1. Fifty-seven cases of “probable” or “proven” IPA were
identified according to the revised standard criteria from
the European Organization for Research and Treatment of
Cancer/Mycology Study Group (EORTC/MSG) (De Pauw et al.,
2008). The control group included patients with no evidence
for the presence of Aspergillus spp. in the BAL (negative
culture and galactomannan testing). Patients with “possible”
disease were excluded from the study and no mold-active
drugs were administered by the treating physician(s) before
sample collection. This study was approved and carried out in
accordance with recommendations of the Ethics Subcommittee
for Life and Health Sciences of the University of Minho,
Portugal, and the Ethics Committee of the University Hospitals
of Leuven, Belgium. Written informed consent was obtained
from all subjects in accordance with the Declaration of
Helsinki.
BAL Fluid Collection
BAL specimens were collected using a flexible fiberoptic
bronchoscope following local anesthesia with 2% lidocaine
(Xylocaine), when infection was clinically suspected. Samples
were obtained by instillation of a pre-warmed 0.9% sterile saline
solution (20mL twice). The sampling area was determined
based on the localization of lesion on chest imaging (X-ray or
computed tomography scan). BAL specimens with comparable
recovery rates were used. All samples were stored at −80◦C
until use.
Frontiers in Microbiology | www.frontiersin.org 2 November 2017 | Volume 8 | Article 2362
Gonçalves et al. Alveolar Cytokines in Aspergillosis
TABLE 1 | Baseline characteristics of patients enrolled in the study.
Variables IPA (n = 57) No IPA (n = 56) P-value
Age, no (%)
≤50 years 9 (15.8) 14 (25.0) 0.25
>50 years 48 (84.2) 42 (75.0)
Gender, no (%)
Female 26 (45.6) 24 (42.9) 0.85
Male 31 (54.4) 32 (57.1)
Underlying disease, no. (%)
SOT† 12 (21.1) 20 (35.7) 0.13
Allogeneic SCT 10 (17.5) 12 (21.4)
Acute leukemia 10 (17.5) 10 (17.9)
Chronic
lymphoproliferative
diseases
10 (17.5) 7 (12.5)
Influenza A (H1N1) 6 (10.5) 0 (0.0)
Chronic lung diseases 4 (7.0) 1 (1.8)
Solid tumors 2 (3.5) 1 (1.8)
Other 3 (5.3) 5 (8.9)
Neutrophil counts,
×103 cells/µL (range)
5.6 (0.0–24.8) 5.2 (1.9–17.3) 0.40
GMI, mean (range) 5 (1.0–6.9) 0.2 (0.1–0.4) <0.001
Other pathogens detected in BAL fluid
Bacteria 8 (14.0) 8 (14.3) 0.42
Viruses 22 (38.6) 10 (17.9)
Fungi‡ 6 (10.5) 3 (5.4)
SOT, solid organ transplantation; SCT, stem-cell transplantation; GMI, galactomannan
index; BAL, bronchoalveolar lavage; P-values were calculated by Fisher’s exact probability
t-test or Student’s t-test for continuous variables.
†
The study included 32 patients who
received an SOT from lung (n = 27), kidney (n = 3), and liver (n = 2). Among those, 12
were diagnosed with IPA (lung, n = 8; kidney, n = 2; and liver, n = 2).
‡
Among fungi,
Pneumocystis spp. was detected in five patients with IPA and three controls.
Galactomannan Testing
The Platelia Aspergillus EIA (Bio-Rad, Marnes-la-Coquette,
France) was used during routine microbiological workup to
detect the presence of galactomannan on uncentrifuged BAL
specimens, as described (D’Haese et al., 2012). The enzyme
immunoassay data was expressed as galactomannan index
(GMI).
ELISA
Cytokines were quantified in BAL and serum samples using
customized Human PremixedMulti-Analyte Kits (R&D Systems,
MN, USA). All cytokine determinations were performed in
duplicates, and concentrations were reported in pg/mL.
Single Nucleotide Polymorphism (SNP)
Selection and Genotyping
SNPs were selected based on previously reported associations
with increased risk of developing IPA (Cunha et al., 2010,
2014) that were independently validated (Chai et al., 2011;
Fisher et al., 2017). Genomic DNA was isolated from whole
blood using the QIAcube automated system (Qiagen, Hilden,
Germany). Genotyping of rs2305619 in PTX3 and rs16910526 in
CLEC7A (dectin-1) was performed using KASPar assays (LGC
Genomics, Hertfordshire, UK) in an Applied Biosystems 7500
Fast Real-Time PCR system (Thermo Fisher Scientific, MA,
USA), according to the manufacturer’s instructions. Mean call
rate for the SNPs was >98%. Quality control for the genotyping
results was achieved with negative controls and randomly
selected samples with known genotypes.
Statistical Analysis
Statistical analyses were performed using the Prism Version
7.0 (GraphPad Software) or R version 3.4.1. P-values <
0.05 were considered statistically significant, unless indicated
otherwise. The concentrations for each cytokine in BAL and
serum specimens were compared between cases of IPA and
controls using either the Student’s t-test or the non-parametric
Mann-Whitney U-test, following the Shapiro-Wilk normality
test. Cytokine levels were expressed as log10 pg/mL, and data
were represented as mean ± SEM. Categorical variables were
compared using the Fisher’s exact test.
Random Forest Analysis (RFA) was used to rank cytokine
levels in importance toward phenotype prediction. Calculations
were carried out tree-by-tree as the random forest was
constructed and were run >100 times to assess the robustness
of ordering using the randomForest package for R. To identify
sets of cytokines whose expression levels were correlated among
patients, an unsupervised hierarchical clustering was applied
using log2 transformed cytokine values. A heatmap was produced
using the Morpheus platform (Broad Institute, MA, USA) using
average linkage on a similarity matrix derived by Pearson
moment correlations between patients (vertical clusters) or
cytokines (horizontal clusters). Cytokine levels in clusters 1
(C1) and 2 (C2) for a given patient were combined by adding
contributions based on the log2 transformed levels of the
individual cytokines, as described (Yan et al., 2011). The median
level for each cluster for all the patients was determined and
patients were evaluated as to whether they were high (“Hi”) or
low (“Lo”) for that cytokine cluster based on their individual
value relative to the median.
The discriminatory ability of each cytokine was measured
as the area under the receiving operating characteristic curve
(AUCROC). Sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), and Youden index
values were computed to evaluate the cytokine thresholds with
the highest discriminatory power. The net reclassification index
(NRI) was used to compare the performance of the identified
cut-off levels of specific cytokines in BAL with other variables,
as indicated.
RESULTS
Alveolar Immune Profiling Reveals a
Subset of Cytokines Differentially
Expressed in IPA
To gain insight into the alveolar cytokine profile associated
with the development of IPA, we compared the levels of single
cytokines in the BAL from patients diagnosed with IPA and
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matched controls. BAL samples from 48 patients with IA and
48 matched controls were available and analyzed for cytokine
levels. From the initial set of 32 analytes tested, we found that
patients with IPA displayed significantly higher levels of IL-1β,
IL-6, IL-8, IL-17A, IL-23, and TNFα after adjusting for multiple
comparisons (Figure 1A; Table S1). Among the differentially
expressed BAL cytokines, random forest analysis (RFA) revealed
that IL-8, IL-6, and IL-23 best differentiated between cases of
IPA and controls, whereas the remaining cytokines displayed an
inconsistent contribution to discrimination (Figure 1B). Levels
of IL-8 were the dominant discriminator, although the full set
distinguished cases from controls. No differences were observed
in the BAL cytokine levels according to the neutropenic status of
the patients with IPA (Figure S1). Consistent with the BAL data,
and despite the globally lower absolute cytokine concentrations
detected in the serum, circulating IL-6, IL-8, IL-17A, and IL-
23 were also significantly increased among patients with IPA
(only IL-17A remained significant after adjustment for multiple
comparisons) (Figure 1C; Table S2).
Two-Dimensional Cluster Analysis Defines
Two BAL Cytokine Sets Related with IPA
Previous studies have shown that cytokines can be released
in clusters, and this coordinated release may reflect common
regulatory mechanisms (Ter Horst et al., 2016). Unsupervised
hierarchal clustering analysis revealed that patients with IPA
clustered separately from controls based on the levels of
individual BAL cytokines (Figure 2A). In addition, two cytokine
sets able to differentiate cases of IPA from controls were defined:
cluster 1 (C1), including IL-6, IL-17A, IL-23, and TNFα, and
cluster 2 (C2), which included IL-1β and IL-8. Further supporting
these results, higher median levels of C1 and C2 cytokines in the
BALweremore frequently observed in patients with IPA (37 C1Hi
and 28 C2Hi patients out of 48) than controls (13 C1Hi and 9 C2Hi
patients out of 48) (Figure 2B). The combined analysis of C1 and
C2 clusters also revealed that higher levels of cytokines from both
clusters were more common among patients with IPA compared
to controls (24 C1Hi/C2Hi patients out of 48) (Figure 2C).
Positivity for Galactomannan Influences
the Levels of BAL Cytokines
The detection of galactomannan in BAL specimens has been
advocated as a sensitive test for diagnosing IPA, particularly when
interpreted in combination with clinical and radiological findings
(D’Haese et al., 2012). To understand whether galactomannan in
the BAL could influence the ability of cytokines to discriminate
cases of IPA from controls, we analyzed individual and
clustered cytokine data according to GMI: <0.5 (identifying
controls), 0.5–2.0 (representing the most commonly used cut-
off values for positivity), and >2.0. We found that patients
with high, but not intermediate, GMI displayed significantly
elevated concentrations of BAL cytokines compared to controls
(Figure 3A). Importantly, only IL-6 and IL-8 retained their
discriminatory potential for IPA in patients with intermediate
FIGURE 1 | A subset of BAL cytokines is differentially expressed in IPA. (A) Levels of cytokines present in the BAL of patients with IPA compared with controls (Ctrl).
Data are presented as mean ± SEM values. (B) Ranking of cytokines by their relative importance in discriminating cases of IPA from controls using RFA. The
horizontal axis represents the average decrease in classification accuracy, and bars indicate the relative importance of each individual cytokine to discrimination. The
dashed line divides cytokines at the mean value of decrease in accuracy and defines the number of cytokines required for maximum classification accuracy. (C) Levels
of cytokines present in the sera of patients with IPA compared with controls (Ctrl). Data are presented as mean ± SEM values.
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FIGURE 2 | Cluster analysis reveals two groups of highly expressed BAL cytokines in IPA. (A) Unsupervised hierarchical clustering for IL-1β, IL-6, IL-8, IL-17A, IL-23,
and TNFα. Expression levels of individual cytokines are represented by shades of blue to red in the heatmap, with highest values in dark red and lowest values in dark
blue. The top dendrogram illustrates the separate clustering of cases of IPA (indicated by gray boxes) from controls (Ctrl) (indicated by green boxes). The left
dendrogram illustrates the identification of two cytokine clusters: C1 (TNFα, IL-23, IL-6, and IL-17A) and C2 (IL-8 and IL-1β). (B) Number of patients presenting low
and high values of C1 (C1Lo and C1Hi, respectively) and C2 cytokines (C2Lo and C2Hi, respectively) among controls (Ctrl) and cases of IPA. (C) Number of patients
with combined information on the levels of C1 and C2 cytokines among controls (Ctrl) and cases of IPA. Four categories are indicated: C1Lo/C2Lo, C1Lo/C2Hi,
C1Hi/C2Lo, C1Hi/C2Hi.
GMI. In addition, by comparing the expression of cytokine
clusters, we found that the C1 profile was not influenced by the
GMI (Figure 3B). Instead, C2Hi patients displayed significantly
higher mean values of GMI than C2Lo patients. Consistent
with this, patients with a combined C1Hi/C2Hi cytokine profile
presented higher mean values of GMI than patients belonging to
the C1Lo/C2Lo category (5.7 vs. 4.0) (Figure 3C).
Genetic Variants Conferring Risk of IPA
Impair the Discriminatory Ability of BAL
Cytokines
A number of studies has disclosed an important contribution of
host genetics in defining susceptibility to IPA (Cunha et al., 2013).
However, with a few exceptions, their consequences to cytokine
production remain elusive. We analyzed cytokine data according
to the genotypes of two of the most robust genetic markers
for IPA identified to date, rs2305619 in PTX3 (Cunha et al.,
2014, 2015; Wojtowicz et al., 2015) and rs16910526 in CLEC7A
(Cunha et al., 2010; Chai et al., 2011). We found that patients
harboring AA or AG (referred to as A+) genotypes at rs2305619
retained increased levels of BAL cytokines when compared to
controls (Figure 4A). However, the production of IL-6 and IL-
8 was significantly impaired by the presence of the high-risk GG
genotype. Accordingly, cluster analysis revealed differences in the
expression of cytokines between cases of IPA and controls with
the A+, but not GG, genotypes (Figure 4B). Similar findings
were observed for the rs16910526 variant in CLEC7A, with
increased levels of BAL cytokines detected in patients carrying
the TT genotype compared to controls (Figure 4C). Production
of IL-1β and IL-23 was instead impaired among patients with
IPA carrying the high-risk TG genotype. As expected, expression
of clustered cytokines was different between cases and controls
with the TT, but not TG, genotypes (Figure 4D). Similar results
were obtained for combined cluster analysis (Figure S2). No
differences were noted in cytokine levels among control subjects
according to the PTX3 or CLEC7A genotypes (data not shown).
BAL Cytokines Represent Potentially
Useful Diagnostic Biomarkers for IPA
To corroborate the utility of BAL cytokines for the diagnosis
of IPA, we analyzed the AUCROC for each cytokine (Figure 5;
Table 2). As expected, all cytokines tested, except for TNFα,
demonstrated reasonable sensitivity and specificity. IL-8 was the
best performing analyte (AUCROC = 0.84; 95% CI, 0.75–0.91;
P<0.001), with a cut-off level of IL-8 ≥904 pg/mL associated
with 90% sensitivity, 73% specificity, 78% PPV, and 88% NPV.
Total accuracy conferred by alveolar IL-8 was 82%: five patients
with IPA presented values below the cut-off, whereas 13 control
subjects displayed instead values above the cut-off.
Consistent with the results pointing to a detrimental role of
specific risk genotypes for IPA regarding cytokine production, we
observed that the high-risk GG genotype at rs2305619 in PTX3
led to a decrease of 23% sensitivity for IL-8 and 29% specificity for
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FIGURE 3 | BAL cytokine levels depend on galactomannan positivity. (A) Levels of alveolar cytokines in patients with negative (<0.5) and different ranges of GMI
positivity (0.5–2.0 and >2.0). Data are presented as mean ± SEM values; ***p < 0.001; **p < 0.01; *p < 0.05. (B) GMI of patients displaying low and high values of
C1 (C1Lo and C1Hi, respectively) and C2 cytokines (C2Lo and C2Hi, respectively). Data are presented as mean ± SEM; **p < 0.01. (C) GMI of patients with
combined information on the levels of C1 and C2 cytokines. Four categories are indicated: C1Lo/C2Lo, C1Lo/C2Hi, C1Hi/C2Lo, C1Hi/C2Hi. Data are presented as
mean ± SEM; *p < 0.05.
IL-6, hindering their performance in identifying cases (AUCROC
= 0.67; 95% CI, 0.33–0.97; P = 0.70) and controls (AUCROC
= 0.58; 95% CI, 0.22–0.89; P = 0.80), respectively (Table S3).
Likewise, the high-risk TG genotype at rs2305619 in CLEC7A
precluded the ability of IL-1β (AUCROC = 0.63; 95% CI, 0.37–
0.89; P = 0.51) and IL-17A (AUCROC = 0.69; 95% CI, 0.41–0.94;
P = 0.21) to identify controls by impairing specificity by 12 and
14%, respectively. Collectively, these results highlight IL-8 as the
most relevant discriminator between cases of IPA and controls
and highlight the genetic background of the patients as a critical
factor to consider when evaluating the diagnostic performance of
host-derived biomarkers.
DISCUSSION
The initiation of an efficient antifungal immune response
depends on a complex set of signals circulating within the
microenvironment, including cytokines and chemokines (Hohl,
2017). Understanding how each of these pathways is regulated
is essential to uncover the molecular and cellular processes
underlying the pathogenesis of IPA, and may also offer crucial
insights toward the identification of molecules that correlate
strongly with infection and the network of signals that could be
therapeutically targeted.
In our exploratory study, we quantified the alveolar levels of 32
analytes in patients with IPA and matched controls, and analyzed
these findings based on individual or analytically clustered sets
of mediators. Our data provide strong evidence for an alveolar
cytokine profile that is differentially expressed in patients with
IPA. The observed inflammatory phenotype is largely attributable
to IPA rather than to a general response to infection since
events of viral, bacterial and even Pneumocystis pneumonia were
diagnosed within the control group (Table 1). This is consistent
with the recent finding that cytokine production is organized
around the physiological response toward specific pathogens
rather than through specific immune pathways (Li et al., 2016).
Prior studies of biomarker evaluation have mostly addressed
candidate cytokines, reporting altered circulating levels to be
correlated with the development of IPA (Camargo and Husain,
2014). In addition, the generation of specific cytokine-producing
T-cells in response to A. fumigatus antigens have also been
exploited as a potential immunodiagnostic approach (Potenza
et al., 2013). Our study is among the first demonstrations that
alveolar cytokines may also be relevant biomarkers for the
diagnosis of IPA, regardless of the neutrophil counts at the time
of diagnosis. In fact, we found that BAL cytokines performed
better than the circulating counterpart, likely because theymirror
more accurately the pathophysiology of IPA, with cytokines
being produced mostly by immune cells at the site of infection
rather than in the periphery (Kontoyiannis, 2011). Of note,
and although galactomannan has been suggested to suppress
cytokine responses (Chai et al., 2009), patients with high GMI
displayed increased levels of alveolar cytokines than controls,
demonstrating that the combination of relevant cytokines with
fungal surrogate markers may improve our capacity to predict
disease outcome.
Within the differential alveolar profile, we identified several
inflammatory cytokines with well-known roles in antifungal
immune responses, such as IL-1β, IL-6, IL-8, and TNFα (Becker
et al., 2015). Among these, IL-8 was the best performing
analyte with a total accuracy above 80%. These findings are
supported by a recent report on a small patient cohort that
also disclosed alveolar IL-8 as a potentially useful biomarker
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FIGURE 4 | Genetic variants conferring risk to IPA influence the levels of BAL cytokines. (A) Levels of alveolar cytokines in patients with IPA carrying different
genotypes at rs2305619 in PTX3. A+ indicates combined AA and AG genotypes. Data are presented as mean ± SEM values; ***p < 0.001, **p < 0.01, *p < 0.05.
(B) Distribution of low and high values of C1 and C2 in IPA and controls (Ctrl) in the presence of different genotypes at rs2305619 in PTX3. Vertical axis represents the
number of patients with low or high values of C1 and C2 while horizontal axis represents the different genotypes; ***p < 0.001, **p < 0.01. (C) Levels of alveolar
cytokines in patients with IPA carrying different genotypes at rs16910526 in CLEC7A. Data are presented as mean ± SEM values; ***p < 0.001, **p < 0.01, *p <
0.05. (D) Distribution of low and high values of C1 and C2 in IPA and controls (Ctrl) in the presence of different genotypes at rs16910526 in CLEC7A. Vertical axis
represents the number of patients with low or high values of C1 and C2 while horizontal axis represents the different genotypes; **p < 0.01.
for IPA (Heldt et al., 2017). This is in accordance with its
role as a central regulatory cytokine produced mainly by
alveolar macrophages and epithelial cells early after infection
to coordinate the recruitment of inflammatory cells (Balloy
et al., 2008). Interestingly, and despite previous reports pointed
to a minor contribution of T helper (Th)17 responses to A.
fumigatus in cellular models of infection (Chai et al., 2010b), IL-
17A and IL-23 in the BAL were also upregulated, supporting
a role for the Th17 pathway during IPA (Zelante et al.,
2007).
The risk of IPA and its clinical outcome vary significantly even
among patients with similar predisposing clinical conditions
and microbiological exposure (Cunha et al., 2013). Although a
number of genetic variants in cytokine genes have also been
associated with the development of IPA (Loeﬄer et al., 2010),
rs2305619 in PTX3 and rs16910526 in CLEC7A have been
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FIGURE 5 | BAL cytokines accurately predict the development of IPA. Area under the receiver operating characteristic curve (AUCROC) analysis for each BAL
cytokine demonstrating sensitivity as a function of one-specificity for the prediction of IPA.
TABLE 2 | Performance of BAL cytokines as diagnostic biomarkers for IPA.
Cytokine Cut-off† Sensitivity Specificity PPV NPV NRI
(95% CI)
IL-1β 27.1 70 (55–83) 68 (55–81) 70 (60–79) 69 (58–78) 0.34
IL-6 89.8 74 (63–85) 79 (68–89) 78 (67–87) 73 (63–81) 0.51
IL-8 904 90 (81–98) 73 (60–85) 78 (68–85) 88 (75–94) 0.63
IL-17A 0.66 72 (58–84) 81 (70–90) 80 (68–88) 74 (64–82) 0.53
IL-23 103 76 (66–90) 77 (67–90) 78 (67–86) 76 (65–84) 0.53
TNF-α 0.94 80 (70–90) 69 (55–81) 73 (63–81) 77 (65–86) 0.49
†
Cut-off values of cytokines are expressed as pg/mL. Statistically-derived optimal cut-
off was determined by Youden’s index (maximum sensitivity and specificity given by the
inflection point of the AUCROC). The net reclassification index (NRI) was used to compare
the performance of each cytokine cut-off with the known diagnosis of IPA. IL, interleukin;
TNF, tumor necrosis factor; PPV, positive predictive value; NPV, negative predictive value.
recently proposed as the most robust genetic markers identified
to date (Fisher et al., 2017). PTX3 is an important fluid-
phase pattern recognition molecule with ancestral antibody-
like properties that recognizes and interacts with A. fumigatus
to exert critical roles in antifungal innate immunity (Garlanda
et al., 2002). Remarkably, IL-6 and IL-8 were influenced by the
presence of the risk genotype at rs2305619, known to impair the
expression of PTX3 in the lung (Cunha et al., 2014). This may
suggest that, similar to other opsonins such as L-ficolin (Bidula
et al., 2015), PTX3-mediated conidia opsonization is critically
required to potentiate IL-8 secretion in the lung. Whatever the
mechanism(s), the functional crosstalk between molecules with
opsonic activity and other inflammatory mediators in antifungal
immunity remains to be thoroughly explored. In any case,
it is not surprising that alveolar, but not serum, PTX3 has
been disclosed as a valuable early marker for microbiologically-
confirmed pneumonia (Mauri et al., 2014).
The levels of IL-1β and IL-17A were instead preferentially
impacted by the genetic deficiency of dectin-1 (Cunha et al.,
2010), highlighting likely different mechanisms through which
these variants confer risk to IPA. The production of IL-1β, a
critical regulator of early Th17 differentiation (Chung et al.,
2009), has been shown to depend on dectin-1 activation (Karki
et al., 2015). In turn, dectin-1-mediated signals were reported
to affect adaptive immunity to A. fumigatus by restraining
Th1 responses and enabling Th17 differentiation (Rivera et al.,
2011). Taken together, these results confirm the importance
of Th17 responses during IPA and highlight the detrimental
consequences of genetic deficiency of dectin-1 to their activation.
Despite its exploratory and unbiased nature, our nested case-
control study presents however certain limitations. The most
relevant regard the inability to conclude about the added benefit
of cytokine measurements compared to galactomannan testing
or fungal PCR, the definition of cytokine levels as the cause or
consequence of the infectious process, and the heterogeneity
of the study population regarding the underlying conditions.
Finally, the number of patients carrying risk-associated genetic
variants do not allow to definitively estimate their effect size
on cytokine levels. However, it also raises interesting questions
that warrant further investigation. For example, functional
studies are required to understand the interrelationships
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among the identified cytokines and the protective vs.
pathophysiological mechanisms underlying IPA, and to
identify therapeutic targets amenable to immunomodulation
(Carvalho et al., 2012a). In conclusion, our results provide
support to additional, well-controlled studies in larger cohorts
evaluating whether the diagnostic potential of cytokines,
particularly in combination with fungal surrogate markers and
integrating the genetic risk profile of the patient, holds clinical
value.
AUTHOR CONTRIBUTIONS
SG, LA-F, CC, and AC designed the study; KL and JM oversaw
patient recruitment and collection of clinical specimens and data;
SG, CR, CFC, and LB-M performed the laboratory assays; SG,
FR, RS, CC, and AC performed the statistical analysis and/or
interpreted the data; all authors critically revised and approved
themanuscript and are accountable for the accuracy and integrity
of the work.
FUNDING
This work was supported by aMérieux Research Grant 2016 from
Institut Mérieux; the Northern Portugal Regional Operational
Programme (NORTE 2020), under the Portugal 2020 Partnership
Agreement, through the European Regional Development Fund
(FEDER) (NORTE-01-0145-FEDER-000013); the Fundação
para a Ciência e Tecnologia (FCT) (IF/00735/2014 and
SFRH/BPD/96176/2013); the Spanish Ministry of Economy and
Competitiveness, Instituto de Salud Carlos III (MPY 1277/15)
(co-financed by the European Development Regional Fund “A
Way to Achieve Europe”); and the Spanish Network for the
Research in Infectious Diseases (REIPI RD12/0015).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2017.02362/full#supplementary-material
REFERENCES
Arvanitis, M., Anagnostou, T., and Mylonakis, E. (2015). Galactomannan and
polymerase chain reaction-based screening for invasive aspergillosis among
high-risk hematology patients: a diagnostic meta-analysis. Clin. Infect. Dis. 61,
1263–1272. doi: 10.1093/cid/civ555
Balloy, V., Sallenave, J. M., Wu, Y., Touqui, L., Latge, J. P., Si-Tahar, M., et al.
(2008). Aspergillus fumigatus-induced interleukin-8 synthesis by respiratory
epithelial cells is controlled by the phosphatidylinositol 3-kinase, p38 MAPK,
and ERK1/2 pathways and not by the toll-like receptor-MyD88 pathway. J. Biol.
Chem. 283, 30513–30521. doi: 10.1074/jbc.M803149200
Becker, K. L., Ifrim, D. C., Quintin, J., Netea, M. G., and Van De Veerdonk, F. L.
(2015). Antifungal innate immunity: recognition and inflammatory networks.
Semin. Immunopathol. 37, 107–116. doi: 10.1007/s00281-014-0467-z
Bidula, S., Sexton, D. W., Abdolrasouli, A., Shah, A., Reed, A., Armstrong-
James, D., et al. (2015). The serum opsonin L-ficolin is detected in lungs
of human transplant recipients following fungal infections and modulates
inflammation and killing of Aspergillus fumigatus. J. Infect. Dis. 212, 234–246.
doi: 10.1093/infdis/jiv027
Bitar, D., Lortholary, O., Le Strat, Y., Nicolau, J., Coignard, B., Tattevin, P.,
et al. (2014). Population-based analysis of invasive fungal infections, France,
2001-2010. Emerg. Infect. Dis. 20, 1149–1155. doi: 10.3201/eid2007.140087
Camargo, J. F., and Husain, S. (2014). Immune correlates of protection in human
invasive aspergillosis. Clin. Infect. Dis. 59, 569–577. doi: 10.1093/cid/ciu337
Carvalho, A., Cunha, C., Bistoni, F., and Romani, L. (2012a).
Immunotherapy of aspergillosis. Clin. Microbiol. Infect. 18, 120–125.
doi: 10.1111/j.1469-0691.2011.03681.x
Carvalho, A., Cunha, C., Iannitti, R. G., Casagrande, A., Bistoni, F., Aversa, F.,
et al. (2012b). Host defense pathways against fungi: the basis for vaccines and
immunotherapy. Front. Microbiol. 3:176. doi: 10.3389/fmicb.2012.00176
Ceesay, M. M., Kordasti, S., Rufaie, E., Lea, N., Smith, M., Wade, J.,
et al. (2016). Baseline cytokine profiling identifies novel risk factors for
invasive fungal disease among haematology patients undergoing intensive
chemotherapy or haematopoietic stem cell transplantation. J. Infect. 73,
280–288. doi: 10.1016/j.jinf.2016.04.040
Chai, L. Y., De Boer, M. G., Van Der Velden, W. J., Plantinga, T. S., Van
Spriel, A. B., Jacobs, C., et al. (2011). The Y238X stop codon polymorphism
in the human beta-glucan receptor dectin-1 and susceptibility to invasive
aspergillosis. J. Infect. Dis. 203, 736–743. doi: 10.1093/infdis/jiq102
Chai, L. Y., Kullberg, B. J., Vonk, A. G., Warris, A., Cambi, A., Latge, J. P., et al.
(2009). Modulation of Toll-like receptor 2 (TLR2) and TLR4 responses by
Aspergillus fumigatus. Infect. Immun. 77, 2184–2192. doi: 10.1128/IAI.01455-08
Chai, L. Y., Netea, M. G., Teerenstra, S., Earnest, A., Vonk, A. G., Schlamm, H. T.,
et al. (2010a). Early proinflammatory cytokines and C-reactive protein trends
as predictors of outcome in invasive aspergillosis. J. Infect. Dis. 202, 1454–1462.
doi: 10.1086/656527
Chai, L. Y., Van De Veerdonk, F., Marijnissen, R. J., Cheng, S. C., Khoo, A. L.,
Hectors, M., et al. (2010b). Anti-Aspergillus human host defence relies on
type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity.
Immunology 130, 46–54. doi: 10.1111/j.1365-2567.2009.03211.x
Chung, Y., Chang, S. H., Martinez, G. J., Yang, X. O., Nurieva, R., Kang, H. S., et al.
(2009). Critical regulation of early Th17 cell differentiation by interleukin-1
signaling. Immunity 30, 576–587. doi: 10.1016/j.immuni.2009.02.007
Cunha, C., Aversa, F., Lacerda, J. F., Busca, A., Kurzai, O., Grube, M., et al. (2014).
Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation.N. Engl.
J. Med. 370, 421–432. doi: 10.1056/NEJMoa1211161
Cunha, C., Aversa, F., Romani, L., and Carvalho, A. (2013). Human
genetic susceptibility to invasive aspergillosis. PLoS Pathog 9:e1003434.
doi: 10.1371/journal.ppat.1003434
Cunha, C., Di Ianni, M., Bozza, S., Giovannini, G., Zagarella, S., Zelante, T., et al.
(2010). Dectin-1 Y238X polymorphism associates with susceptibility to invasive
aspergillosis in hematopoietic transplantation through impairment of both
recipient- and donor-dependent mechanisms of antifungal immunity. Blood
116, 5394–5402. doi: 10.1182/blood-2010-04-279307
Cunha, C., Goncalves, S. M., Duarte-Oliveira, C., Leite, L., Lagrou, K., Marques,
A., et al. (2017). IL-10 overexpression predisposes to invasive aspergillosis by
suppressing antifungal immunity. J. Allergy Clin. Immunol. 140, 867.e9–870.e9.
doi: 10.1016/j.jaci.2017.02.034
Cunha, C., Monteiro, A. A., Oliveira-Coelho, A., Kuhne, J., Rodrigues, F., Sasaki,
S. D., et al. (2015). PTX3-based genetic testing for risk of aspergillosis
after lung transplant. Clin. Infect. Dis. 61, 1893–1894. doi: 10.1093/cid/
civ679
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra,
T., et al. (2008). Revised definitions of invasive fungal disease from the
European Organization for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG)
Consensus Group. Clin. Infect. Dis. 46, 1813–1821. doi: 10.1086/
588660
D’Haese, J., Theunissen, K., Vermeulen, E., Schoemans, H., De Vlieger, G.,
Lammertijn, L., et al. (2012). Detection of galactomannan in bronchoalveolar
lavage fluid samples of patients at risk for invasive pulmonary aspergillosis:
analytical and clinical validity. J. Clin. Microbiol. 50, 1258–1263.
doi: 10.1128/JCM.06423-11
Frontiers in Microbiology | www.frontiersin.org 9 November 2017 | Volume 8 | Article 2362
Gonçalves et al. Alveolar Cytokines in Aspergillosis
Espinosa, V., and Rivera, A. (2016). First line of defense: innate cell-
mediated control of pulmonary aspergillosis. Front. Microbiol. 7:272.
doi: 10.3389/fmicb.2016.00272
Fisher, C. E., Hohl, T. M., Fan, W., Storer, B. E., Levine, D. M., Zhao,
L. P., et al. (2017). Validation of single nucleotide polymorphisms in
invasive aspergillosis following hematopoietic cell transplantation. Blood 129,
2693–2701. doi: 10.1182/blood-2016-10-743294
Garlanda, C., Hirsch, E., Bozza, S., Salustri, A., De Acetis, M., Nota, R.,
et al. (2002). Non-redundant role of the long pentraxin PTX3 in anti-
fungal innate immune response. Nature 420, 182–186. doi: 10.1038/nature
01195
Heldt, S., Eigl, S., Prattes, J., Flick, H., Rabensteiner, J., Pruller, F., et al. (2017).
Levels of interleukin (IL)-6 and IL-8 are elevated in serum and bronchoalveolar
lavage fluid of haematological patients with invasive pulmonary aspergillosis.
Mycoses. doi: 10.1111/myc.12679. [Epub ahead of print].
Hohl, T. M. (2017). Immune responses to invasive aspergillosis: new
understanding and therapeutic opportunities. Curr. Opin. Infect. Dis. 30,
364–371. doi: 10.1097/QCO.0000000000000381
Karki, R., Man, S. M., Malireddi, R. K., Gurung, P., Vogel, P., Lamkanfi, M.,
et al. (2015). Concerted activation of the AIM2 and NLRP3 inflammasomes
orchestrates host protection against Aspergillus infection. Cell Host Microbe 17,
357–368. doi: 10.1016/j.chom.2015.01.006
Kontoyiannis, D. P. (2011). Are serum cytokines sensitive and specific enough
to prognosticate in aspergillosis? J. Infect. Dis. 203, 1503; author reply 1504.
doi: 10.1093/infdis/jir050
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie,
E. J., Walsh, T. J., et al. (2010). Prospective surveillance for invasive
fungal infections in hematopoietic stem cell transplant recipients, 2001-
2006: overview of the Transplant-Associated Infection Surveillance Network
(TRANSNET) Database. Clin. Infect. Dis. 50, 1091–1100. doi: 10.1086/6
51263
Kozel, T. R., andWickes, B. (2014). Fungal diagnostics. Cold Spring Harb. Perspect.
Med. 4:a019299. doi: 10.1101/cshperspect.a019299
Li, Y., Oosting, M., Smeekens, S. P., Jaeger, M., Aguirre-Gamboa, R., Le,
K. T., et al. (2016). A functional genomics approach to understand
variation in cytokine production in humans. Cell 167, 1099.e14–1110.e14.
doi: 10.1016/j.cell.2016.10.017
Loeﬄer, J., Ok, M., Morton, O. C., Mezger, M., and Einsele, H. (2010).
Genetic polymorphisms in the cytokine and chemokine system: their possible
importance in allogeneic stem cell transplantation. Curr. Top. Microbiol.
Immunol. 341, 83–96. doi: 10.1007/82_2010_22
Maertens, J. A., Raad, I.i, Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely,
O. A., et al. (2016). Isavuconazole versus voriconazole for primary treatment
of invasive mould disease caused by Aspergillus and other filamentous fungi
(SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387,
760–769. doi: 10.1016/S0140-6736(15)01159-9
Mauri, T., Coppadoro, A., Bombino, M., Bellani, G., Zambelli, V., Fornari, C.,
et al. (2014). Alveolar pentraxin 3 as an early marker of microbiologically
confirmed pneumonia: a threshold-finding prospective observational study.
Crit Care 18:562. doi: 10.1186/s13054-014-0562-5
Mezger, M., Steffens, M., Beyer, M., Manger, C., Eberle, J., Toliat, M. R.,
et al. (2008). Polymorphisms in the chemokine (C-X-C motif) ligand
10 are associated with invasive aspergillosis after allogeneic stem-cell
transplantation and influence CXCL10 expression in monocyte-derived
dendritic cells. Blood 111, 534–536. doi: 10.1182/blood-2007-05-0
90928
Morrissey, C. O., Chen, S. C., Sorrell, T. C., Milliken, S., Bardy, P. G., Bradstock,
K. F., et al. (2013). Galactomannan and PCR versus culture and histology for
directing use of antifungal treatment for invasive aspergillosis in high-risk
haematology patients: a randomised controlled trial. Lancet Infect. Dis. 13,
519–528. doi: 10.1016/S1473-3099(13)70076-8
Oliveira-Coelho, A., Rodrigues, F., Campos, A. Jr., Lacerda, J. F., Carvalho,
A., and Cunha, C. (2015). Paving the way for predictive diagnostics and
personalized treatment of invasive aspergillosis. Front. Microbiol. 6:411.
doi: 10.3389/fmicb.2015.00411
Pagano, L., Caira, M., Candoni, A., Offidani, M., Martino, B., Specchia,
G., et al. (2010). Invasive aspergillosis in patients with acute myeloid
leukemia: a SEIFEM-2008 registry study. Haematologica 95, 644–650.
doi: 10.3324/haematol.2009.012054
Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A.,
Freifeld, A., et al. (2010). Invasive fungal infections among organ transplant
recipients: results of the Transplant-Associated Infection Surveillance Network
(TRANSNET). Clin. Infect. Dis. 50, 1101–1111. doi: 10.1086/651262
Potenza, L., Vallerini, D., Barozzi, P., Riva, G., Forghieri, F., Beauvais, A., et al.
(2013). Characterization of specific immune responses to different Aspergillus
antigens during the course of invasive Aspergillosis in hematologic patients.
PLoS ONE 8:e74326. doi: 10.1371/journal.pone.0074326
Reikvam, H., Mosevoll, K. A., Melve, G. K., Gunther, C. C., Sjo, M., Bentsen, P.
T., et al. (2012). The pretransplantation serum cytokine profile in allogeneic
stem cell recipients differs from healthy individuals, and various profiles are
associated with different risks of posttransplantation complications. Biol. Blood
Marrow Transplant. 18, 190–199. doi: 10.1016/j.bbmt.2011.10.007
Rivera, A., Hohl, T. M., Collins, N., Leiner, I., Gallegos, A., Saijo, S., et al.
(2011). Dectin-1 diversifies Aspergillus fumigatus-specific T cell responses by
inhibiting T helper type 1 CD4T cell differentiation. J. Exp. Med. 208, 369–381.
doi: 10.1084/jem.20100906
Segal, B. H. (2009). Aspergillosis. N. Engl. J. Med. 360, 1870–1884.
doi: 10.1056/NEJMra0808853
Shen, H. P., Tang, Y. M., Song, H., Xu, W. Q., Yang, S. L., and Xu, X. J. (2016).
Efficiency of interleukin 6 and interferon gamma in the differentiation of
invasive pulmonary aspergillosis and pneumocystis pneumonia in pediatric
oncology patients. Int. J. Infect. Dis. 48, 73–77. doi: 10.1016/j.ijid.2016.05.016
Ter Horst, R., Jaeger, M., Smeekens, S. P., Oosting, M., Swertz, M. A., Li, Y., et al.
(2016). Host and environmental factors influencing individual human cytokine
responses. Cell 167, 1111.e13–1124.e13. doi: 10.1016/j.cell.2016.10.018
Wojtowicz, A., Gresnigt, M. S., Lecompte, T., Bibert, S., Manuel, O., Joosten, L.
A., et al. (2014). IL1B and DEFB1 polymorphisms increase susceptibility to
invasive mold infection after solid-organ transplantation. J. Infect. Dis. 211,
1646–1657. doi: 10.1093/infdis/jiu636
Wojtowicz, A., Lecompte, T. D., Bibert, S., Manuel, O., Rueger, S., Berger, C., et al.
(2015). PTX3 polymorphisms and invasive mold infections after solid organ
transplant. Clin. Infect. Dis. 61, 619–622. doi: 10.1093/cid/civ386
Yan, X. J., Dozmorov, I., Li,W., Yancopoulos, S., Sison, C., Centola,M., et al. (2011).
Identification of outcome-correlated cytokine clusters in chronic lymphocytic
leukemia. Blood 118, 5201–5210. doi: 10.1182/blood-2011-03-342436
Zelante, T., De Luca, A., Bonifazi, P., Montagnoli, C., Bozza, S., Moretti,
S., et al. (2007). IL-23 and the Th17 pathway promote inflammation and
impair antifungal immune resistance. Eur. J. Immunol. 37, 2695–2706.
doi: 10.1002/eji.200737409
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Gonçalves, Lagrou, Rodrigues, Campos, Bernal-Martínez,
Rodrigues, Silvestre, Alcazar-Fuoli, Maertens, Cunha and Carvalho. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Microbiology | www.frontiersin.org 10 November 2017 | Volume 8 | Article 2362
